Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial

Shitara K., Doi T., Dvorkin M., Mansoor W., Arkenau H., Prokharau A., ...More

LANCET ONCOLOGY, vol.19, no.11, pp.1437-1448, 2018 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 19 Issue: 11
  • Publication Date: 2018
  • Doi Number: 10.1016/s1470-2045(18)30739-3
  • Journal Name: LANCET ONCOLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.1437-1448
  • Hacettepe University Affiliated: Yes


Background Trifluridine/tipiracil showed activity and was well tolerated in a phase 2 study of pretreated patients with advanced gastric cancer done in Japan. We investigated whether the treatment was efficacious compared with placebo in a global population.